Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Advent

Sanofi reception

Sanofi moves to replace Medivation board

Ramps up efforts to seize control of its US biopharma takeover target

- PMLiVE

Victoza cuts cardiovascular risk in landmark study

Novo Nordisk’s diabetes therapy outcomes ‘beyond expectations’

Sanofi reception

Sanofi boosted by iGlarLixi trials at ADA

Combination of Lantus and Lyxumia showed greater efficacy in controlling type 2 diabetes

Deal Watch May 2016

Novartis, Quintiles and Sanofi are among those featured in this month’s round-up of pharma deal activity

- PMLiVE

GSK and J&J move closer to sirukumab filing for arthritis

On course for third quarter application in a bid to catch up with Sanofi’s sarilumab

Biogen Idec building

Biogen and AbbVie bag FDA approval for multiple sclerosis drug

Once-monthly, self-administered Zinbryta ‘significantly’ reduces relapse rate

National Institute for Health and Care Excellence NICE logo

NICE gives green light to Sanofi’s Jevtana for prostate cancer

Undisclosed discount for NHS encourages U-turn to back the chemotherapy drug

Sanofi reception

FDA panel backs Sanofi’s insulin/GLP-1 agonist combo

iGlarLixi secures endorsement despite concern over its dosing and delivery device

Sanofi Pascale Witz

Sanofi’s diabetes head Pascale Witz to leave the company

She will be replaced by Peter Guenter as part of an executive reshuffle

- PMLiVE

Sanofi appoints Pfizer’s Rita Balice-Gordon to lead neurobiology research

She will be based at the firm's Framingham, Massachusetts R&D site

National Institute for Health and Care Excellence NICE logo

NICE persuaded to back Praluent as well as Repatha

Comes after Sanofi follows Amgen in discounting the price of its drug

Deal Watch March 2016

AstraZeneca, Roche, Sanofi and Valeant are featured in this month’s roundup of pharma deals

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links